Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care. In this video, she speaks about the Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer.
Â
The goal of this study is to define the performance characteristics (sensitivity and specificity) of the Helio Liver Test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been confirmed to be cancer-free by at least one imaging technique, such as ultrasound, MRI, or CT. Individuals who are at high risk for liver cancer and have been advised to undergo liver cancer surveillance will serve as control subjects, as will patients with non-HCC malignancies to determine analytical specificity.
